Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried (MCV2) developed by
Tianjin Cansino Biotechnology has been approved for clinical trial by China Food and Drug
Administration (approval number: 2015L05221).
We received the clinical trial application acceptance notice in May, 2013 and submitted the
materials to Center for Drug Evaluation (CDE) in December, 2013. MCV2 of Cansino is used
for 3 months infants to 2 years old children, which can elicit memory immune responses for
the prevention of epidemic cerebrospinal meningitis caused by Group A and C meningococcal.
Meningococcal meningitis is a life-threatening acute respiratory disease caused by Neisseria
meningitidis (meningococcus). As a widespread invasive infection, it is associated with high
mortality and drug resistance due to high mutation frequency of meningococca.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2